HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.

We have cloned and characterized a novel human gene, HGAL (human germinal center-associated lymphoma), which predicts outcome in patients with diffuse large B-cell lymphoma (DLBCL). The HGAL gene comprises 6 exons and encodes a cytoplasmic protein of 178 amino acids that contains an immunoreceptor tyrosine-based activation motif (ITAM). It is highly expressed in germinal center (GC) lymphocytes and GC-derived lymphomas and is homologous to the mouse GC-specific gene M17. Expression of the HGAL gene is specifically induced in B cells by interleukin-4 (IL-4). Patients with DLBCL expressing high levels of HGAL mRNA demonstrate significantly longer overall survival than do patients with low HGAL expression. This association was independent of the clinical international prognostic index. High HGAL mRNA expression should be used as a prognostic factor in DLBCL.

[1]  Ash A. Alizadeh,et al.  The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.

[2]  P. Pavlidis,et al.  Cutting Edge: STAT6 Serves as a Positive and Negative Regulator of Gene Expression in IL-4-Stimulated B Lymphocytes1 , 2002, The Journal of Immunology.

[3]  R. Rees,et al.  Th1/Th2 Cytokine Expression and its Relationship with Tumor Growth in B Cell Non-Hodgkin's Lymphoma (NHL) , 2002, Leukemia & lymphoma.

[4]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[5]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[6]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[7]  R Tibshirani,et al.  Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. , 2001, Blood.

[8]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[9]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[11]  Ash A. Alizadeh,et al.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Kumazawa,et al.  Absence of interleukin-4 enhances germinal center reaction in secondary immune response. , 2000, Immunology letters.

[13]  R. Tibshirani,et al.  Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. , 2000, Blood.

[14]  I. Lossos,et al.  Mutation analysis of the 5' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity. , 2000, Blood.

[15]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[16]  J Hermans,et al.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.

[17]  Klaus Rajewsky,et al.  Somatic hypermutation in normal and transformed human B cells , 1998, Immunological reviews.

[18]  Y. S. Choi,et al.  The functional role of B cell antigen receptor stimulation and IL-4 in the generation of human memory B cells from germinal center B cells. , 1997, Journal of immunology.

[19]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[20]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[21]  D C Linch,et al.  Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.

[22]  U. Storb,et al.  The molecular basis of somatic hypermutation of immunoglobulin genes. , 1996, Current opinion in immunology.

[23]  P. Gaulard,et al.  Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma , 1996 .

[24]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[25]  K. Offit,et al.  Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Cambier,et al.  Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). , 1995, Journal of immunology.

[27]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[28]  K. Rajewsky,et al.  M17: a novel gene expressed in germinal centers. , 1994, International immunology.

[29]  I. Maclennan Germinal centers. , 1994, Annual review of immunology.

[30]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[31]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[32]  J. Rossi,et al.  Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. , 1992, Blood.

[33]  Charles W. Taylor,et al.  Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms , 1990 .

[34]  T. Grogan,et al.  Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. , 1990, Blood.

[35]  B. Beutler,et al.  Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[36]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .